- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted therapies for ER+/HER2- metastatic breast cancer
Authors
Keywords
Breast cancer, Targeted therapy, Cancer genome, Endocrine therapy resistance
Journal
BMC Medicine
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-06-11
DOI
10.1186/s12916-015-0369-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Breast Cancer, Version 3.2013
- (2017) Richard L. Theriault et al. Journal of the National Comprehensive Cancer Network
- Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
- (2015) Ilenia Migliaccio et al. BMC Medicine
- Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping
- (2015) Lisette Binkhorst et al. CANCER TREATMENT REVIEWS
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†
- (2014) F. Cardoso et al. ANNALS OF ONCOLOGY
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
- (2014) Sadhna R. Vora et al. CANCER CELL
- Emergence of Constitutively Active Estrogen Receptor- Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
- (2014) R. Jeselsohn et al. CLINICAL CANCER RESEARCH
- First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
- (2014) D. Sarker et al. CLINICAL CANCER RESEARCH
- Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer
- (2014) Fabrice André et al. CURRENT MEDICAL RESEARCH AND OPINION
- Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
- (2014) Jordi Rodon et al. INVESTIGATIONAL NEW DRUGS
- Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
- (2014) Ingrid A. Mayer et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
- (2014) Fabrice André et al. LANCET ONCOLOGY
- Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
- (2014) M. Yu et al. SCIENCE
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
- (2013) Denise A. Yardley et al. ADVANCES IN THERAPY
- Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer
- (2013) Xiaoyong Fu et al. BREAST
- Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study
- (2013) H Iwase et al. BRITISH JOURNAL OF CANCER
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2013) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
- (2013) F. Andre et al. CLINICAL CANCER RESEARCH
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
- (2013) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- PI3K in cancer–stroma interactions: bad in seed and ugly in soil
- (2013) E Hirsch et al. ONCOGENE
- Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms
- (2013) A Ali et al. Cell Death & Disease
- Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients
- (2012) Roberta Ferraldeschi et al. BREAST CANCER RESEARCH AND TREATMENT
- Abstract 1: Oncogenic extracellular domain mutations of ERBB2 in cancer
- (2012) Heidi Greulich et al. CANCER RESEARCH
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Appropriate Design of Prospective Studies
- (2012) Jung-Hye Choi et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- (2012) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
- (2012) Patrick J. Roberts et al. JNCI-Journal of the National Cancer Institute
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- (2011) P N Munster et al. BRITISH JOURNAL OF CANCER
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Endocrine Resistance in Breast Cancer
- (2010) C. Kent Osborne et al. Annual Review of Medicine
- Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors
- (2010) L. Wang et al. CANCER RESEARCH
- FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
- (2010) N. Turner et al. CANCER RESEARCH
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
- (2009) Matthew J. Ellis et al. BREAST CANCER RESEARCH AND TREATMENT
- Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling
- (2009) Christina Gewinner et al. CANCER CELL
- Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array
- (2009) F. Andre et al. CLINICAL CANCER RESEARCH
- Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor–Positive, Aromatase Inhibitor–Resistant Advanced Breast Cancer
- (2009) Matthew J. Ellis et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now